NDAORALCAPSULE, EXTENDED RELEASE
Approved
Apr 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
INDERAL LA (propranolol hydrochloride) by ANI Pharmaceuticals is clinical pharmacology general propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. First approved in 1983.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INDERAL LA (propranolol hydrochloride) is a non-selective beta-adrenergic receptor antagonist formulated as an extended-release oral capsule for once-daily dosing. It is indicated for the management of hypertension, angina pectoris, and migraine headache prophylaxis. The drug works by blocking beta-adrenergic receptors, reducing cardiac output, heart rate, and blood pressure, while also decreasing myocardial oxygen demand. INDERAL LA represents the long-acting formulation of a legacy antihypertensive and antianginal agent that has been standard therapy since FDA approval in 1983.
$0.0BPart D
Mechanism of Action
CLINICAL PHARMACOLOGY General Propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor-stimulating agents for available receptor sites. When access to beta-receptor sites is…
Worked on INDERAL LA at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.